2024-09-01 - Analysis Report
## Lilly (LLY) Stock Analysis

**Company Overview:** Lilly is a leading pharmaceutical company that develops, manufactures, and markets pharmaceutical products for various diseases. 

**Performance Analysis:**

1. **Performance vs. S&P 500 (VOO):**
   - Lilly's cumulative return is significantly higher than the S&P 500 (571.94% vs. 89.66%).
   - The relative divergence shows that Lilly has outperformed the S&P 500 by a significant margin (100.0%).
   - This suggests that Lilly has been a strong performer historically compared to the overall market.

2. **Recent Price Movement:**
   - Current price: $960.02
   - 5-day moving average: $950.83
   - 20-day moving average: $907.01
   - 60-day moving average: $888.73
   - The stock is currently trading above its moving averages, suggesting potential upward momentum.

3. **Technical Indicators:**
   - **RSI (78.82):** Indicates the stock is currently in overbought territory.
   - **PPO (0.36):** Suggests that the price momentum is positive.
   - **Delta_Previous_Relative_Divergence (18.98):** Shows that the stock has experienced a recent short-term price surge.
   - The high RSI and positive PPO signal potential for further gains, but the overbought condition might lead to a short-term correction.

4. **Recent Earnings and Outlook:**

| Date       | EPS      | Revenue     |
|-------------|----------|-------------|
| 2024-08-08 | 3.29     | 11.30 B$    |
| 2024-04-30 | 2.49     | 8.77 B$     |
| 2023-11-02 | -0.06    | 9.50 B$     |
| 2023-08-08 | 1.96     | 8.31 B$     |
| 2024-08-08 | 1.96     | 8.31 B$     | 

- **Most recent earnings:** Lilly's most recent earnings (2024-08-08) surpassed analysts' expectations, with an EPS of 3.29, exceeding the estimated 2.95.
- **Earnings growth:** Lilly has demonstrated consistent revenue and earnings growth over the last few quarters.
- **Outlook:**  Analysts remain optimistic about Lilly's future prospects, driven by its strong pipeline of promising drugs and continued growth in existing products.

**Overall Analysis:**

Lilly has consistently outperformed the broader market and demonstrates robust fundamentals. The stock is currently trading in overbought territory, which might indicate a potential short-term correction. However, the positive technical indicators and strong earnings suggest potential for further growth in the long term. Investors with a long-term horizon may find Lilly to be a solid investment option. 
